The Voice of a Special Patient

  • Stefan Aebi
Part of the Cancer Treatment and Research book series (CTAR, volume 151)

What is the meaning of “special” in the context of breast cancer or, in particular, of this book? Dictionary definitions encompass distinguished from what is ordinary or usual, of a distinct or particular kind or character, particularly valued, having a particular function or purpose, or simply additional; extra [1]. The title of this chapter was proposed by the editor but I do not feel “special” in any of the above senses, and I do not intend to use my author privilege, only to give an additional testimony of my coping with breast cancer.

The reader may recognize that the adjective “special” is derived from the Latin root “specio”, an archaic word meaning “I see” or “I look at.” “Species”, a derived Latin noun with female grammatical gender, is usually translated by “sight, appearance”, “kind” or “type”. In addition to “special”, a large number of derived words are commonly used in contemporary English, such as suspicious, perspective, respect, spectrum, conspicuous, aspect, specimen,...


Breast Cancer Sentinel Lymph Node Sentinel Lymph Node Biopsy Emotional Labor Grammatical Gender 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Random House. "special". In: Costello RB, ed. Random House Webster's College Dictionary. 1995 ed. New York: Random House, Inc.; 1995:1284–5.Google Scholar
  2. 2.
    Ernout A, Meillet A. Dictionnaire étymologique de la langue latine – Histoire des mots. In. 4 ed. Paris: Editions Klincksieck; 1985:639–41.Google Scholar
  3. 3.
    Walde A, Hofmann JB. Lateinisches etymologisches Wörterbuch. Heidelberg: Carl Winter's Universitätsbuchhandlung; 1938.Google Scholar
  4. 4.
    Jemal A, Siegel R, Ward E, et al. Cancer Statistics, CA Cancer J Clin. 2006;56(2):106–30.PubMedCrossRefGoogle Scholar
  5. 5.
    Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: A population-based study. Cancer. 2004;101(1):51–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997;60(2):313–9.PubMedGoogle Scholar
  7. 7.
    Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60(5):1079–84.PubMedGoogle Scholar
  8. 8.
    Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res. 2002;4(1):R2.PubMedCrossRefGoogle Scholar
  9. 9.
    Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367(9510):595–604.PubMedCrossRefGoogle Scholar
  10. 10.
    Cimmino VM, Degnim AC, Sabel MS, Diehl KM, Newman LA, Chang AE. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol. 2004;86(2):74–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Goyal A, Horgan K, Kissin M, et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol. 2004;30(5):480–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: Results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995;31A(12):1960–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001;182(4):389–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003;127(1):36–41.PubMedGoogle Scholar
  15. 15.
    Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104(11):2359–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: Metabolic effects. J Clin Endocrinol Metab. 2000;85(7):2370–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J Clin Endocrinol Metab. 2004;89(3):1174–80.PubMedCrossRefGoogle Scholar
  18. 18.
    de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M. Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab. 2005;7(3):211–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Mauras N, Lima J, Patel D, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab. 2003;88(12):5951–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Labrie F, Dupont A, Belanger A, et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: A case report. Clin Invest Med. 1990;13(5):275–8.PubMedGoogle Scholar
  21. 21.
    Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer. 1993;72(2):502–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer. 1988;62(3):474–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer. J Surg Oncol. 2005;90(1):26–30.PubMedCrossRefGoogle Scholar
  24. 24.
    Italiano A, Largillier R, Marcy PY, et al. [Complete remission obtained with letrozole in a man with metastatic breast cancer]. Rev Med Interne. 2004;25(4):323–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol. 2002;25(3):235–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Phase II study of goserelin and anastrozole in men with estrogen receptor – or progesterone receptor-positive recurrent or metastatic breast cancer. SWOG S-0511. 2005; Available at Accessed January 14, 2007
  27. 27.
    Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available at Accessed December, 7 2006.
  28. 28.
    Efficace F, Therasse P, Piccart MJ, et al. Health-Related Quality of Life Parameters As Prognostic Factors in a Nonmetastatic Breast Cancer Population: An International Multicenter Study. J Clin Oncol. 2004;22(16):3381–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Goodwin PJ, Ennis M, Bordeleau LJ, et al. Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. J Clin Oncol. 2004;22(20):4184–92.PubMedCrossRefGoogle Scholar
  30. 30.
    Markes M, Brockow T, Resch KL. Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev. 2006(4):CD005001.Google Scholar
  31. 31.
    Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293(20):2479–86.PubMedCrossRefGoogle Scholar
  32. 32.
    Nielsen NR, Gronbaek M. Stress and breast cancer: A systematic update on the current knowledge. Nat Clin Pract Oncol. 2006;3(11):612–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Ramirez AJ, Craig TK, Watson JP, Fentiman IS, North WR, Rubens RD. Stress and relapse of breast cancer. BMJ. 1989;298(6669):291–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Graham J, Ramirez A, Love S, Richards M, Burgess C. Stressful life experiences and risk of relapse of breast cancer: Observational cohort study. BMJ. 2002;324(7351):1420–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Barraclough J, Pinder P, Cruddas M, Osmond C, Taylor I, Perry M. Life events and breast cancer prognosis. BMJ. 1992;304(6834):1078–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Maunsell E, Brisson J, Mondor M, Verreault R, Deschenes L. Stressful Life Events and Survival After Breast Cancer. Psychosom Med. 2001;63(2):306–15.PubMedGoogle Scholar
  37. 37.
    Clinical Trials. Available at Accessed January 14, 2007.
  38. 38.
    Hearn J, Sullivan R. The impact of the ‘Clinical Trials’ directive on the cost and conduct of non-commercial cancer trials in the UK. Eur J Cancer. 2007;43(1):8–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Iredale R, Brain K, Williams B, France E, Gray J. The experiences of men with breast cancer in the United Kingdom. Eur J Cancer. 2006;42(3):334–41.PubMedCrossRefGoogle Scholar
  40. 40.
    Larson EB, Yao X. Clinical empathy as emotional labor in the patient-physician relationship. JAMA. 2005;293(9):1100–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Breast and Gynecological Cancer Center, Departments of Medical Oncology and GynecologyUniversity HospitalInselspitalSwitzerland

Personalised recommendations